Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), Formulation (Cream, Gel, Spray, Patch, and Others) and Distribution Channel (Pharmacies & Drug Stores, e-Commerce, and Retail & Grocery Stores) - Global Opportunity Analysis and Industry Forecast, 2017-2025
- ALL2617109
- 275 Pages
- June 2018
- Healthcare
Pain treatment involves usage of common analgesics or painkillers to reduce and treat body pain. Whenever, these analgesics are applied directly to the skin they are known as topical pain relief medications. These include topical administration of drugs such as non-steroidal anti-inflammatory drugs, anesthetics, capsaicin, tricyclic antidepressants, ketamine, clonidine, opioids, and cannabinoids. Topical pain relief medications exert peripheral effects near the site of application and minimize the pain. Topical formulations used for pain relief include creams, ointments, gels, and newly developed drug-delivery systems, usually transdermal patches. They are mostly available as over-the-counter (OTC) products while some are available through prescription only.
The global topical pain relief market was valued at $7,481 million in 2017, and is projected to reach $13,276 million by 2025 at a CAGR of 7.4% from 2018 to 2025. Increase in prevalence of arthritis is the major factor that contributes towards the growth of the topical pain relief market. Moreover, other factors that fuel the market growth include growth in geriatric population, lesser side effects caused due to use of topical analgesics as compared to oral pain relief, and high demand for topical pain relief by sports players. However, topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that impede the market growth. Conversely, development of online platform for the topical therapeutics and high market potential in untapped emerging economies are expected to provide lucrative opportunities for the market growth.
The global topical pain relief market is segmented into therapeutic class, type, formulation, distribution channel, and region. Based on therapeutic class, the market is divided into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. Based on type, the market is segmented into prescription pain relief and over-the-counter (OTC) relief. Based on the formulation, the market is classified into cream, gel, spray, patch, and others. The distribution channels covered in the study include pharmacies & drug stores, e-commerce, and retail & grocery stores. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS
- The study provides an in-depth analysis of the global topical pain relief market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Key market segments
By Therapeutic Class
- Non-opioids
- Nonsteroidal anti-inflammatory drug (NSAIDS)
- Methyl Salicylate
- Capsaicin
- Lidocaine
- Other Non-opioids
- Opioids
- Buprenorphine
- Fentanyl
By Type
- Prescription Pain Relief
- Over-the-counter (OTC) Pain Relief
By Formulation
- Cream
- Gel
- Spray
- Patch
- Others
By Formulation
- Pharmacies & Drug Stores
- e-Commerce
- Retail & Grocery Stores
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Johnson & Johnson
- Novartis AG
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Reckitt Benckiser Group Plc.
- Sanofi S.A.
- Topical BioMedics, Inc.
- AdvaCare Pharma
- Sun Pharmaceutical Industries Ltd.
- Nestle S.A.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Troy Healthcare, LLC
- Emami Group
- Chattem, Inc.
- Exzell Pharma
- Performance Health Technologies, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. By Therapeutic Class
1.3.2. By Type
1.3.3. By Formulation
1.3.4. By Distribution Channel
1.3.5. By Region
1.3.6. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of arthritis
3.4.1.2. Growth in geriatric population
3.4.1.3. High demand for topical pain relief products by sportsperson
3.4.1.4. Lesser side effects caused by topical pain relief products as compared to oral medicines
3.4.2. Restraints
3.4.2.1. Topical pain relief sometimes cause skin irritants
3.4.2.2. Topical pain relief are characterized by unpleasant odor
3.4.3. Opportunities
3.4.3.1. Emergence of online pharmacy
3.4.3.2. Opportunities in emerging economies
3.4.4. Impact analyses
3.5. Patent analysis (2013-2018)
3.5.1. Patent analysis, by year
3.5.2. Patent analysis for U.S., by year
CHAPTER 4: TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Non-opioids
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDS)
4.2.2.1.1. Market size and forecast, by region
4.2.2.2. Methyl salicylates
4.2.2.2.1. Market size and forecast, by region
4.2.2.3. Capsaicin
4.2.2.3.1. Market size and forecast, by region
4.2.2.4. Lidocaine
4.2.2.4.1. Market size and forecast, by region
4.2.2.5. Other Non-Opioids
4.2.2.5.1. Market size and forecast, by region
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Opioids
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Buprenorphine
4.3.2.1.1. Market size and forecast, by region
4.3.2.2. Fentanyl
4.3.2.2.1. Market size and forecast, by region
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
CHAPTER 5: TOPICAL PAIN RELIEF MARKET, BY FORMULATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cream
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Gel
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Spray
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Patch
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: TOPICAL PAIN RELIEF MARKET, BY TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Prescription pain relief
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Over-the-counter pain relief
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7: TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Pharmacies & drug stores
7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country
7.3. e-Commerce
7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country
7.4. Grocery stores
7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country
CHAPTER 8: TOPICAL PAIN RELIEF MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. North America topical pain relief market, by country
8.2.2.1. U.S.
8.2.2.1.1. Market size and forecast, by therapeutic class
8.2.2.1.2. Market size and forecast, by formulation
8.2.2.1.3. Market size and forecast, by type
8.2.2.1.4. Market size and forecast, by distribution channel
8.2.2.2. Canada
8.2.2.2.1. Market size and forecast, by therapeutic class
8.2.2.2.2. Market size and forecast, by formulation
8.2.2.2.3. Market size and forecast, by type
8.2.2.2.4. Market size and forecast, by distribution channel
8.2.2.3. Mexico
8.2.2.3.1. Market size and forecast, by therapeutic class
8.2.2.3.2. Market size and forecast, by formulation
8.2.2.3.3. Market size and forecast, by type
8.2.2.3.4. Market size and forecast, by distribution channel
8.2.3. North America market size and forecast, by therapeutic class
8.2.4. North America market size and forecast, by formulation
8.2.5. North America market size and forecast, by type
8.2.6. North America market size and forecast, by distribution channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Europe market size and forecast, by country
8.3.2.1. Germany
8.3.2.1.1. Market size and forecast, by therapeutic class
8.3.2.1.2. Market size and forecast, by formulation
8.3.2.1.3. Market size and forecast, by type
8.3.2.1.4. Market size and forecast, by distribution channel
8.3.2.2. France
8.3.2.2.1. Market size and forecast, by therapeutic class
8.3.2.2.2. Market size and forecast, by formulation
8.3.2.2.3. Market size and forecast, by type
8.3.2.2.4. Market size and forecast, by distribution channel
8.3.2.3. UK
8.3.2.3.1. Market size and forecast, by therapeutic class
8.3.2.3.2. Market size and forecast, by formulation
8.3.2.3.3. Market size and forecast, by type
8.3.2.3.4. Market size and forecast, by distribution channel
8.3.2.4. Italy
8.3.2.4.1. Market size and forecast, by therapeutic class
8.3.2.4.2. Market size and forecast, by formulation
8.3.2.4.3. Market size and forecast, by type
8.3.2.4.4. Market size and forecast, by distribution channel
8.3.2.5. Spain
8.3.2.5.1. Market size and forecast, by therapeutic class
8.3.2.5.2. Market size and forecast, by formulation
8.3.2.5.3. Market size and forecast, by type
8.3.2.5.4. Market size and forecast, by distribution channel
8.3.3. Rest of Europe
8.3.3.1.1. Market size and forecast, by therapeutic class
8.3.3.1.2. Market size and forecast, by formulation
8.3.3.1.3. Market size and forecast, by type
8.3.3.1.4. Market size and forecast, by distribution channel
8.3.4. Europe market size and forecast, by therapeutic class
8.3.5. Europe market size and forecast, by formulation
8.3.6. Europe market size and forecast, by type
8.3.7. Europe market size and forecast, by distribution channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Asia-Pacific market size and forecast, by country
8.4.2.1. Japan
8.4.2.1.1. Market size and forecast, by therapeutic class
8.4.2.1.2. Market size and forecast, by type
8.4.2.1.3. Market size and forecast, by type
8.4.2.1.4. Market size and forecast, by distribution channel
8.4.2.2. China
8.4.2.2.1. Market size and forecast, by therapeutic class
8.4.2.2.2. Market size and forecast, by formulation
8.4.2.2.3. Market size and forecast, by type
8.4.2.2.4. Market size and forecast, by distribution channel
8.4.2.3. India
8.4.2.3.1. Market size and forecast, by therapeutic class
8.4.2.3.2. Market size and forecast, by formulation
8.4.2.3.3. Market size and forecast, by type
8.4.2.3.4. Market size and forecast, by distribution channel
8.4.2.4. Australia
8.4.2.4.1. Market size and forecast, by therapeutic class
8.4.2.4.2. Market size and forecast, by formulation
8.4.2.4.3. Market size and forecast, by type
8.4.2.4.4. Market size and forecast, by distribution channel
8.4.2.5. South Korea
8.4.2.5.1. Market size and forecast, by therapeutic class
8.4.2.5.2. Market size and forecast, by formulation
8.4.2.5.3. Market size and forecast, by type
8.4.2.5.4. Market size and forecast, by distribution channel
8.4.2.6. Rest of Asia-Pacific
8.4.2.6.1. Market size and forecast, by therapeutic class
8.4.2.6.2. Market size and forecast, by formulation
8.4.2.6.3. Market size and forecast, by type
8.4.2.6.4. Market size and forecast, by distribution channel
8.4.3. Asia-Pacific market size and forecast, by therapeutic class
8.4.4. Asia-Pacific market size and forecast, by formulation
8.4.5. Asia-Pacific market size and forecast, by type
8.4.6. Asia-Pacific market size and forecast, by distribution channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. LAMEA market size and forecast, by country
8.5.2.1. Brazil
8.5.2.1.1. Market size and forecast, by therapeutic class
8.5.2.1.2. Market size and forecast, by formulation
8.5.2.1.3. Market size and forecast, by type
8.5.2.1.4. Market size and forecast, by distribution channel
8.5.2.2. Saudi Arabia
8.5.2.2.1. Market size and forecast, by therapeutic class
8.5.2.2.2. Market size and forecast, by formulation
8.5.2.2.3. Market size and forecast, by type
8.5.2.2.4. Market size and forecast, by distribution channel
8.5.2.3. South Africa
8.5.2.3.1. Market size and forecast, by therapeutic class
8.5.2.3.2. Market size and forecast, by formulation
8.5.2.3.3. Market size and forecast, by type
8.5.2.3.4. Market size and forecast, by distribution channel
8.5.2.4. Rest of LAMEA
8.5.2.4.1. Market size and forecast, by therapeutic class
8.5.2.4.2. Market size and forecast, by formulation
8.5.2.4.3. Market size and forecast, by type
8.5.2.4.4. Market size and forecast, by distribution channel
8.5.3. LAMEA market size and forecast, by therapeutic class
8.5.4. LAMEA market size and forecast, by formulation
8.5.5. LAMEA market size and forecast, by type
8.5.6. LAMEA market size and forecast, by distribution channel
CHAPTER 9: COMPANY PROFILES
9.1. AdvaCare Pharma
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product Portfolio
9.2. GlaxoSmithKline plc.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product Portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments
9.3. Johnson & Johnson
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product Portfolio
9.3.5. Business performance
9.4. Nestl S.A.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product Portfolio
9.4.5. Business performance
9.5. Novartis AG
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product Portfolio
9.5.5. Business performance
9.6. Pfizer Inc.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product Portfolio
9.6.5. Business performance
9.7. Reckitt Benckiser Group plc
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product Portfolio
9.7.5. Business performance
9.8. Sanofi
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product Portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments
9.9. Sun Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product Portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments
9.10. Topical BioMedics, Inc.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product Portfolio
9.10.5. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 02. GLOBAL TOPICAL NON-OPIOIDS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 03. GLOBAL TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 04. GLOBAL TOPICAL METHYL SALICYLATES MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 05. GLOBAL TOPICAL CAPSAICIN MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 06. GLOBAL TOPICAL LIDOCAINE MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 07. GLOBAL TOPICAL OTHER NON-OPIOIDS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 08. GLOBAL TOPICAL NON-OPIOIDS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 09. GLOBAL TOPICAL OPIOIDS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 10. GLOBAL TOPICAL BUPRENORPHINE MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 11. GLOBAL TOPICAL FENTANYL MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 12. GLOBAL TOPICAL OPIOIDS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 13. GLOBAL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 14. GLOBAL TOPICAL PAIN RELIEF CREAM MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 15. GLOBAL TOPICAL PAIN RELIEF GEL MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 16. GLOBAL TOPICAL PAIN RELIEF SPRAY MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 17. GLOBAL TOPICAL PAIN RELIEF PATCH MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 18. GLOBAL TOPICAL PAIN RELIEF OTHERS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 19. GLOBAL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 20. GLOBAL PRESCRIPTION TOPICAL PAIN RELIEF MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 21. GLOBAL OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 22. GLOBAL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 23. GLOBAL TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES, BY REGION, 2017-2025 ($MILLION)
TABLE 24. GLOBAL TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE, BY REGION, 2017-2025 ($MILLION)
TABLE 25. GLOBAL TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS, BY REGION, 2017-2025 ($MILLION)
TABLE 26. GLOBAL TOPICAL PAIN RELIEF MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 27. NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 28. U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 29. U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 30. U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 31. U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 32. CANADA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 33. CANADA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 34. CANADA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 35. CANADA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 36. MEXICO TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 37. MEXICO TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 38. MEXICO TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 39. MEXICO TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 40. NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 41. NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 42. NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 43. NORTH AMERICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 44. EUROPE TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 45. GERMANY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 46. GERMANY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 47. GERMANY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 48. GERMANY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 49. FRANCE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 50. FRANCE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 51. FRANCE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 52. FRANCE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 53. UK TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 54. UK TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 55. UK TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 56. UK TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 57. ITALY TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 58. ITALY TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 59. ITALY TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 60. ITALY TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 61. SPAIN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 62. SPAIN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 63. SPAIN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 64. SPAIN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 65. REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 66. REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 67. REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 68. REST OF EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 69. EUROPE TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 70. EUROPE TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 71. EUROPE TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 72. EUROPE TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 73. ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 74. JAPAN TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 75. JAPAN TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 76. JAPAN TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 77. JAPAN TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 78. CHINA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 79. CHINA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 80. CHINA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 81. CHINA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 82. INDIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 83. INDIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 84. INDIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 85. INDIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 86. AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 87. AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 88. AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 89. AUSTRALIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 90. SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 91. SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 92. SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 93. SOUTH KOREA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 98. ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 99. ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 100. ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 101. ASIA-PACIFIC TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 102. LAMEA TOPICAL PAIN RELIEF MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 103. BRAZIL TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 104. BRAZIL TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 105. BRAZIL TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 106. BRAZIL TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 107. SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 108. SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 109. SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 110. SAUDI ARABIA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 111. SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 112. SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 113. SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 114. SOUTH ARICA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 115. REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 116. REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 117. REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 118. REST OF LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 119. LAMEA TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017-2025 ($MILLION)
TABLE 120. LAMEA TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017-2025 ($MILLION)
TABLE 121. LAMEA TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 122. LAMEA TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 ($MILLION)
TABLE 123. ADVACARE: COMPANY SNAPSHOT
TABLE 124. ADVACARE: BUSINESS SEGMENTS
TABLE 125. ADVACARE: PRODUCT PORTFOLIO
TABLE 126. GSK: COMPANY SNAPSHOT
TABLE 127. GSK: OPERATING SEGMENTS
TABLE 128. GSK: PRODUCT PORTFOLIO
TABLE 129. J&J: COMPANY SNAPSHOT
TABLE 130. J&J: OPERATING SEGMENTS
TABLE 131. J&J: PRODUCT PORTFOLIO
TABLE 132. NESTL: COMPANY SNAPSHOT
TABLE 133. NESTL: OPERATING SEGMENTS
TABLE 134. NESTL: PRODUCT PORTFOLIO
TABLE 135. NOVARTIS: COMPANY SNAPSHOT
TABLE 136. NOVARTIS: OPERATING SEGMENTS
TABLE 137. NOVARTIS: PRODUCT PORTFOLIO
TABLE 138. PFIZER: COMPANY SNAPSHOT
TABLE 139. PFIZER: OPERATING SEGMENTS
TABLE 140. PFIZER: PRODUCT PORTFOLIO
TABLE 141. RB: COMPANY SNAPSHOT
TABLE 142. RB: OPERATING SEGMENTS
TABLE 143. RB: PRODUCT PORTFOLIO
TABLE 144. SANOFI: COMPANY SNAPSHOT
TABLE 145. SANOFI: OPERATING SEGMENTS
TABLE 146. SANOFI: PRODUCT PORTFOLIO
TABLE 147. SUN PHARMA: COMPANY SNAPSHOT
TABLE 148. SUN PHARMA: OPERATING SEGMENTS
TABLE 149. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 150. TOPICAL BIOMEDICS: COMPANY SNAPSHOT
TABLE 151. TOPICAL BIOMEDICS: OPERATING SEGMENTS
TABLE 152. TOPICAL BIOMEDICS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. TOPICAL PAIN RELIEF MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. ESTIMATED AND PROJECTED NUMBER OF ADULTS WITH DOCTOR-DIAGNOSED ARTHRITIS IN THE U.S., 2000-2024 (IN MILLIONS)
FIGURE 05. NUMBER OF ELDERLY POPULATION IN THE U.S., AND GERMANY, 2010-2014 (IN PERCENTAGE)
FIGURE 06. IMPACT ANALYSES
FIGURE 07. PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2018
FIGURE 08. PATENTS ANALYSIS BY YEAR, 2013 THROUGH 2017
FIGURE 09. U.S. PATENT ANALYSIS, BY YEAR
FIGURE 10. COMPARATIVE ANALYSIS OF TOPICAL NON-OPIOIDS MARKET, 2017 & 2025 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF TOPICAL OPIOIDS MARKET, 2017 & 2025 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF CREAM MARKET, 2017 & 2025 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF GEL MARKET, 2017 & 2025 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF SPRAY MARKET, 2017 & 2025 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF PATCH MARKET, 2017 & 2025 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF OTHERS TOPICAL PAIN RELIEF MARKET, 2017 & 2025 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF PRESCRIPTION PAIN RELIEF MARKET, 2017 & 2025 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TOPICAL PAIN RELIEF MARKET, 2017 & 2025 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR PHARMACIES & DRUG STORES, 2017 & 2025 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR E-COMMERCE, 2017 & 2025 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF TOPICAL PAIN RELIEF MARKET FOR REATIL & GROCERY SHOPS, 2017 & 2025 ($MILLION)
FIGURE 22. PERCENTAGE OF PEOPLE WITH DIFFERENT TYPES OF PAIN IN U.S., 2015
FIGURE 23. PREVALENCE OF OSTEOARTHRITIS BY GENDER AND AGE GROUP IN GERMANY, 2013 (IN PERCENTAGE)
FIGURE 24. GSK: REVENUE, 2015-2017 ($MILLION)
FIGURE 25. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. J&J: REVENUE, 2015-2017 ($MILLION)
FIGURE 28. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30. NESTL: REVENUE, 2015-2017 ($MILLION)
FIGURE 31. NESTL: REVENUE SHARE BY OPERATING SEGMENT, 2017 (%)
FIGURE 32. NESTL.: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 34. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 36. PFIZER: REVENUE, 2015-2017 ($MILLION)
FIGURE 37. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 38. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. RB: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. RB: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. RB: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. SANOFI: NET SALES, 2015-2017 ($MILLION)
FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 45. SUN PHARMA: NET SALES, 2015-2017 ($MILLION)
FIGURE 46. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 47. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
